Amgen announces Phase 3 results of Imdelltra with AstraZeneca’s Imfinzi
Amgen (AMGN) reported Phase 3 results showing Imdelltra with AstraZeneca’s (AZN) Imfinzi reduced death risk by 58% in extensive stage small cell lung cancer, extending median overall survival to 21.1 months. Data was presented at ESMO Congress 2026 and published in The New England Journal of Medicine.
How this was made
The 30-second read
Why it matters
The trial's positive outcomes could accelerate regulatory filings and increase market confidence in both companies' oncology pipelines.
Market read
New Phase 3 data represent a material catalyst for both Amgen and AstraZeneca, likely influencing stock movements and sector sentiment.
What to watch
Regulatory review timelines and potential safety signals not yet disclosed.
Background
The data were presented at the ESMO 2026 Congress and published in NEJM, marking the first public disclosure of these interim results.
Ticker impact
Amgen reported interim Phase 3 data showing Imdelltra + Imfinzi cut death risk by 58% and extended median OS to 21.1 months.
upward pressure as investors price in improved survival outcomes
Phase 3 interim results are material for a biotech and often trigger price gains.
AstraZeneca's Imfinzi, combined with Amgen's Imdelltra, demonstrated a 58% reduction in death risk in ES‑SCLC patients.
moderate upside as market credits the combo's efficacy
Positive data for a partnered indication can improve investor sentiment toward the partner.
Market effects
Strengthens the oncology segment outlook and may boost related biotech stocks.
Positive for US biotech market; European partners also benefit.
Highlights progress in small cell lung cancer treatment worldwide.
Counterpoint
Skeptics may question durability of interim data and long-term survival benefit.
Key entities
- companyAmgen
Biotech firm developing Imdelltra.
- companyAstraZeneca
Pharma company providing Imfinzi.
